Memorial Sloan Kettering medical oncologist Louise Ligresti

Louise Ligresti, MD

Medical Oncologist

Clinical Expertise

Breast Cancer; Cervical Cancer; Uterine (Endometrial) Cancer; Ovarian Cancer; Uterine Sarcoma

New Patient Appointments

Scheduling a visit is easy. Click below or call us to get started.

Accepted Insurance Providers

Dr. Ligresti accepts the following list of insurance providers. Select your insurance provider to see more details.

Contact and Location

Locations map

Find a Convenient Location

Memorial Sloan Kettering has locations throughout New York City, Long Island, New Jersey, and Westchester. These locations offers many services, including screening, chemotherapy, and medical testing.

About Me


MD, SUNY Syracuse


Internal Medicine - New York Hospital/Weill Cornell Medical College


Hematology/Oncology - Memorial Sloan Kettering Cancer Center

Board Certifications

Medical Oncology; Hematology

Awards and Honors

  • Castle Connolly Top Doctors: New York Metro Area, 2011-2016


Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.

Clinical Trials

Smiling doctors in the lab

Find a Clinical Trial for You

Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.

You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.

Research and Publications

Riccio L, Hudis C, Holmes F, Seidman A, Raptis G, Baselga J, Fennelly D, Theodoulou M, Gilewski T, Currie V, Moynahan M, Surbone A, Sklarin N, Maickel N, Usakewicz J, Uhlenhopp M, Hortobagyi G, Norton L.  Phase II study of semi-synthetic paclitaxel in patients with metastatic breast cancer previously treated with one chemotherapy regimen.  Proc Am Soc Clin Oncol 15:82, 1996; Poster presentation:  American Society of Clinical Oncology Meeting, Philadelphia, PA, 1996

Hudis C, Seidman A, Raptis G, Baselga J, Fennelly D, Theodoulou M, Gilewski T, Currie V, Moynahan M, Surbone A, Sklarin N, Robles M, Riccio L, Yao TJ, Uhlenhopp M, Norton L.  Sequential dose-dense Doxorubicin (A)-Paclitaxel (P)-Cyclophosphamide (C) is less toxic than A-concurrent T+C as adjuvant therapy in resected node positive breast cancer.  Proc Am Soc Clin Oncol 15:8, 1996

Riccio L, Hudis C, Seidman A, Baselga J, Currie V, Fennelly D, Gilewski T, Lebwohl D, Moynahan M, Raptis G, Surbone A, Sklarin N, Yao TJ, Keefe D, and Norton L.  Lack of increased cardiac toxicity with sequential doxorubicin and paclitaxel.  Cancer Invest 1998; 16(2):67-71

Hudis C, Fornier M, Riccio L, Lebwohl D, Crown J, Gilewski T, Surbone A, Currie V, Seidman A, Reichman B, Moynahan M, Raptis G, Sklarin N, Theodoulou M, Weiselberg L, Salvaggio R, Panageas DS, Yao TJ, and Norton L.  5-Year Results of Dose-Intensive Sequential Adjuvant Chemotherapy for Women with High-Risk Node-Positive Breast Cancer:  A Phase II Study.  J Clin Oncol 1999 Apr; 17(4):1118